Clinical Trials Consumption DEA Treatment 
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.
Veriheal
AUGUST 31, 2020
Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death. Nishtha Tripathi. Program between St.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
MARCH 21, 2019
Although the DEA refuses to remove marijuana from the schedule 1 list, the Farm Bill is considered to be the most important victory in the history of U.S. In 2017, Kentucky approved the House Bill 333 that legalized the consumption and retail sale of CBD containing up to 0.3% You can find the list of medical conditions here.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015. Fabricio A.
Expert insights. Personalized for you.
52 
Let's personalize your content